SRTS on XNAS, Health Care, Sensus Healthcare, Inc, job postings
Measures activity, not value. Not investment advice.
Revenue fell 53% to $16.6M and the stock is down 42% in a year, but insiders bought $260K.
BadNet loss $16M over 12 months, with free cash outflow $11.5M
Written by AI from the data on this page, 22 Nov 2026. Not investment advice.
Profile and fundamentals
From its SEC filings, 12 months to 30 Sep 2026
Sensus Healthcare Inc is engaged in manufacturing a superficial radiotherapy system. These devices are used for treating both oncological and non-oncological skin conditions including basal cell and squamous cell skin cancers and other skin conditions such as keloids. Its product includes SRT-100, SRT-100 vision, and a sentinel service program. The company's revenue is generated majorly from customers in the United States.
Industry
Surgical & medical instruments & apparatus (Health Care)
expected around 11 Feb 2027 (an estimate: a year ago it reported on 12 Feb 2026)
Revenue and net income per quarter. Quarter to 30 Sep 2026: revenue $6.0M, net loss $1.5M.
31 Dec 2021RevenueNet incomeNet losstallest bar $16.1M30 Sep 2026
See the numbers
Quarter to
Revenue
Net income
30 Sep 2026
$6.0M
-$1.5M
30 Jun 2026
$2.3M
-$8.7M
31 Mar 2026
$3.4M
-$2.6M
31 Dec 2025
$4.9M
-$3.2M
30 Sep 2025
$6.9M
-$943K
30 Jun 2025
$7.3M
-$1.0M
31 Mar 2025
$8.3M
-$2.6M
31 Dec 2024
$13.1M
$1.5M
30 Sep 2024
$8.8M
$1.2M
30 Jun 2024
$9.2M
$1.6M
31 Mar 2024
$10.7M
$2.3M
31 Dec 2023
$12.6M
$4.2M
30 Sep 2023
$3.9M
-$1.5M
30 Jun 2023
$4.5M
-$380K
31 Mar 2023
$3.4M
-$1.9M
31 Dec 2022
$13.1M
$2.8M
30 Sep 2022
$9.0M
$1.8M
30 Jun 2022
$12.1M
$3.5M
31 Mar 2022
$10.3M
$16.1M
31 Dec 2021
$13.0M
$5.3M
Fundamentals, 12 months to 30 Sep 2026
Measure
Latest
Year before
Peer median
RevenueiSales over the last 12 months reported.
$16.6M
$35.6M
Revenue growthiRevenue of the last 12 months compared with the 12 months before.
-53%
+13%
Net incomeiProfit after all costs and taxes over the last 12 months reported. Negative is a loss.
-$16.0M
-$3.0M
EPS (diluted)iEarnings per share: net income divided by the shares, counting options and convertibles. Left blank when the figures as filed do not fit today's share count (after a split).
-$0.97
-$0.18
Gross marginiWhat is left of each dollar of sales after the direct cost of making the product or service.
41.8%
48.0%
60.5%
Operating marginiOperating income as a share of sales: profit from the business before interest and taxes.
-74.0%
-15.3%
-8.3%
Net marginiNet income as a share of sales: what the owners keep of each dollar sold.
-96.5%
-8.4%
-10.1%
Return on equityiNet income of the last 12 months divided by shareholders' equity (the average of the latest balance sheet and the one a year earlier): the profit made on the owners' money.
-37.0%
-26.3%
Free cash flowiCash from operations minus capital spending over the last 12 months: cash the business produced.
-$11.5M
–
CashiCash, cash equivalents and short-term investments on the latest balance sheet.
$12.9M
$24.5M
DebtiShort- and long-term borrowings on the latest balance sheet. Operating leases are not counted.
$0
$0
Net debtiDebt minus cash. Negative means the company holds more cash than it owes (net cash).
-$12.9M (net cash)
-$24.5M
Debt to equityiDebt divided by shareholders' equity on the latest balance sheet: how much is borrowed for each dollar the owners have in the company. Blank when equity is negative.
0.0
0.31
Book value per shareiShareholders' equity (assets minus liabilities) on the latest balance sheet divided by the shares outstanding.
$2.15
P/EiPrice to earnings: market cap divided by net income of the last 12 months. What investors pay for one dollar of yearly profit. Blank when the company made a loss.
loss
28.0
P/SiPrice to sales: market cap divided by revenue of the last 12 months.
2.2
2.3
EV/SalesiEnterprise value (market cap plus debt minus cash) divided by revenue of the last 12 months.
1.5
2.5
P/BiPrice to book: market cap divided by shareholders' equity on the latest balance sheet. Blank when equity is negative.
1.0
2.8
Latest = 12 months to 30 Sep 2026; balance-sheet lines at its end. Peer median: companies in the same industry (SIC code), or the sector when the industry is small.
Peers nearest by market cap, its own industry first
Insider buy/sell iShares the company's insiders (directors, officers and owners of 10% or more) bought minus what they sold on the open market in the last 90 days, from their Form 4 filings.
+$824K
bought $824K, sold $0
Institutional holders iThe number of institutional investment managers (13F filers: funds, pensions, asset managers) reporting the stock, compared with the quarter before. 13F reports are public 45 days after quarter end and show long positions only.
-5.3%
36 13F filers vs 38
Institutional ownership iShares held by 13F filers at the latest quarter end, divided by the shares outstanding in the company's latest filing. Above 100% usually means a stale share count or double counting, and is marked.
22%
3.5M shares held by 13F filers (30 Sep 2026) of 16.5M outstanding (10 Nov 2026)
Short interest iShares sold short and not yet bought back, divided by the shares outstanding in the company's latest filing. From FINRA's latest short interest report: FINRA reports twice a month and publishes 7 business days after the settlement date. Above 100% means a stale share count, and is marked.
1.4%
222K shares sold short (30 Oct 2026) of 16.5M outstanding (10 Nov 2026)
Days to cover iShort interest divided by the stock's average daily trading volume, as FINRA publishes it: how many days of normal trading it would take short sellers to buy back every share. Latest report.
7.2
222K shares sold short (30 Oct 2026) divided by the stock's average daily volume, as FINRA publishes it
Short interest change iHow the number of shares sold short changed between FINRA's two latest reports, about two weeks apart.
-3.3%
230K shares sold short in the report before, 222K on 30 Oct 2026
Short sale volume iShare of the stock's latest daily volume on FINRA-reported off-exchange venues that was sold short. Market makers sell short routinely, so 40% to 50% is normal; compare it with the company's own 1-year average in the cell's details. A daily flow, not short interest.
15%
15% of off-exchange volume on 20 Nov 2026 was short sales; 1-year average 38%
Lobbying iWhat the company reported spending on federal lobbying over the last four quarters.
$35K
4 quarters
News iArticles about the company published in the last 7 days, from our Google News collection (one search per company, every half hour). Blank when we do not collect news for this company.
19
19 articles in the last 7 days; its usual week has 0 (the median of the 26 weeks before).
News vs usual iArticles in the last 7 days divided by the company's usual week: the median week of the 26 weeks before. Blank when the usual week has fewer than one article.
–
19 articles in the last 7 days; its usual week has 0: fewer than one, so there is nothing to compare with.
Unusual now sharp changes in the last 90 days, compared with its own past
Insider buying $260K, 3 insiders
Price $2.26 on 20 Nov 2026, -42% over 12 months (12-month range $2.26 to $5.30)
Sharp change
8-K and other filings
Lobbying filing
Insider net buying (open market). Insiders bought a net $836K in the last 12 months (the 12 months before: $160K).Revenue per quarter. Revenue $6.0M in the latest quarter, -13% on a year earlier.Capital spending per quarter. Capital spending $5K in the latest quarter, +25% on a year earlier.Institutional holders (13F filers). 36 13F filers reported holding it in the latest 13F quarter, -7.7% on a year earlier.Lobbying spend. Lobbying spend: $35K published in the last 12 months, -59% on the 12 months before.
Every point sits on the day the fact became public (filing acceptance or publication), not the day it happened; prices through 20 Nov 2026. Hover or tap a marker for the fact; click it for the evidence or the source. No data here for: h-1b/e-3 applications certified, federal obligations, workers in warn layoff notices.
Reported lobbying spend: $35K in Q4 2025, $65K in Q3 2025. Rows are lobbying firms hired or let go; amounts are reported per quarter, not per firm here.
Date
Change
Lobbying firm
Issue
Source
31 Dec 2025
Ended
Brian Glackin & Associates LLCfor Capitol Advocacy & Government Affairs, LLC (On Behalf Of Sensus Healthcare)
Skin cancer treatment and prevention issues.Health issues
Two or more unrelated kinds of records unusual within 30 days
13 Dec 2022confirmed
Confirmed across sources Institutional holdings and Short interest and volume
Sensus Healthcare(SRTS): saw 30 13F filers open a new position in the quarter ended 30 Sep 2022, 30× the same quarter last year, while it had 1.5M shares sold short in the 15 Dec 2022 report, 14× the same report last year. Two unrelated kinds of activity within 49 days.
Institutional holdings: Many funds opening a new position, became public on 14 Nov 2022
Short interest and volume: Short interest spike, became public on 10 Dec 2022
Short interest and volume: Short interest spike, became public on 28 Dec 2022
The quarter ended 30 Sep 2022 against the 8 quarters before it.
this quarterearliernormal: 3.5See the evidence (3 changes)
Institutional holdings: Many funds opening a new position became public on 14 Nov 2022
Sensus Healthcare saw 30 13F filers open a new position in the quarter ended 30 Sep 2022, 30× the same quarter last year.
This period
30 (the quarter ended 30 Sep 2022)
Normal quarter (median of 8 earlier)
3.5
Typical spread (median absolute deviation)
3
How far from its usual level
+6.0
Same quarter last year
1
History used
2,283 days
the quarter ended 30 Sep 20228 earlier quartersnormal: 3.5
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 6+ earlier periods, 730+ days of history and a value of at least 20.
Short interest and volume: Short interest spike became public on 10 Dec 2022
Sensus Healthcare had 1.4M shares sold short in the 30 Nov 2022 report, 14× the same report last year.
This period
1.4M (the 30 Nov 2022 report)
Normal report (median of 24 earlier)
379K
Typical spread (median absolute deviation)
148K
How far from its usual level
+4.6
Same report last year
102K
History used
1,797 days
the 30 Nov 2022 report24 earlier reportsnormal: 379K
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
Short interest and volume: Short interest spike became public on 28 Dec 2022
Sensus Healthcare had 1.5M shares sold short in the 15 Dec 2022 report, 14× the same report last year.
This period
1.5M (the 15 Dec 2022 report)
Normal report (median of 24 earlier)
388K
Typical spread (median absolute deviation)
148K
How far from its usual level
+4.9
Same report last year
102K
History used
1,812 days
the 15 Dec 2022 report24 earlier reportsnormal: 388K
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
Several things at once means two or more unrelated kinds of records changed sharply within 30 days. Records that come from the same documents (for example filings and the financials taken from them) count as one kind.
Timeline
Changes and notable records, by the date each became public
19 Nov 2026Insiders change
had 3 insiders buy $260K of its shares on the open market within 30 days (3 filings).
Who bought: Sardano Joseph C, Sachetta Eric, Cornish Megan.
Fires when at least 3 independent insiders (joint filers count once) buy on the open market in 30 days, in at least 2 filings, for $100K or more in total; amendments do not count.
Fires when at least 3 independent insiders (joint filers count once) buy on the open market in 30 days, in at least 2 filings, for $100K or more in total; amendments do not count.
had 1.2M shares sold short in the 14 Feb 2025 report, 24× the same report last year.
Same report last year: 49K; its normal report is 458K.
See the evidence
This period
1.2M (the 14 Feb 2025 report)
Normal report (median of 24 earlier)
458K
Typical spread (median absolute deviation)
102K
How far from its usual level
+4.8
Same report last year
49K
History used
2,604 days
the 14 Feb 2025 report24 earlier reportsnormal: 458K
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
had 1.5M shares sold short in the 31 Jan 2025 report, 41× the same report last year.
Same report last year: 38K; its normal report is 445K.
See the evidence
This period
1.5M (the 31 Jan 2025 report)
Normal report (median of 24 earlier)
445K
Typical spread (median absolute deviation)
115K
How far from its usual level
+6.5
Same report last year
38K
History used
2,590 days
the 31 Jan 2025 report24 earlier reportsnormal: 445K
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
had 1.4M shares sold short in the 15 Jan 2025 report, 35× the same report last year.
Same report last year: 39K; its normal report is 439K.
See the evidence
This period
1.4M (the 15 Jan 2025 report)
Normal report (median of 24 earlier)
439K
Typical spread (median absolute deviation)
121K
How far from its usual level
+5.1
Same report last year
39K
History used
2,574 days
the 15 Jan 2025 report24 earlier reportsnormal: 439K
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
had 1.2M shares sold short in the 31 Dec 2024 report, 35× the same report last year.
Same report last year: 34K; its normal report is 424K.
See the evidence
This period
1.2M (the 31 Dec 2024 report)
Normal report (median of 24 earlier)
424K
Typical spread (median absolute deviation)
136K
How far from its usual level
+3.9
Same report last year
34K
History used
2,559 days
the 31 Dec 2024 report24 earlier reportsnormal: 424K
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
had 536K shares sold short in the 31 Oct 2024 report, 9.8× the same report last year.
Same report last year: 55K; its normal report is 67K.
See the evidence
This period
536K (the 31 Oct 2024 report)
Normal report (median of 24 earlier)
67K
Typical spread (median absolute deviation)
42K
How far from its usual level
+7.6
Same report last year
55K
History used
2,498 days
the 31 Oct 2024 report24 earlier reportsnormal: 67K
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
had 586K shares sold short in the 15 Oct 2024 report, 23× the same report last year.
Same report last year: 26K; its normal report is 60K.
See the evidence
This period
586K (the 15 Oct 2024 report)
Normal report (median of 24 earlier)
60K
Typical spread (median absolute deviation)
35K
How far from its usual level
+10.2
Same report last year
26K
History used
2,482 days
the 15 Oct 2024 report24 earlier reportsnormal: 60K
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
had 532K shares sold short in the 30 Sep 2024 report, 11× the same report last year.
Same report last year: 47K; its normal report is 54K.
See the evidence
This period
532K (the 30 Sep 2024 report)
Normal report (median of 24 earlier)
54K
Typical spread (median absolute deviation)
25K
How far from its usual level
+9.6
Same report last year
47K
History used
2,467 days
the 30 Sep 2024 report24 earlier reportsnormal: 54K
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
Showing the newest 40 of 91 entries; narrow the window or the kind of data to see older ones.
Not listed: 195 routine records (quarterly and annual reports, results releases, other 8-K items, material agreements and individual insider sales), counted over all history.
Identifiers and sources
How records are matched to this company, and what each source holds for it
Cik
0001494891
Ticker
SRTS
Domain
sensushealthcare.com
Hq location
FL|BOCA RATON|33487 (1 unverified)
Lobbying client
capitol advocacy and government affairs llc on behalf of sensus healthcare, sensus healthcare
Name
Sensus Healthcare, Inc
Federal lobbying disclosures (LDA)10 records, 53 data points20 Nov 2013 to 31 Dec 2025
SEC Form 13F institutional holdings378 data points30 Jun 2016 to 30 Sep 2026
SEC EDGAR filings (8-K items, S-1, Form D, 10-K/10-Q)126 records4 Jan 2016 to 13 Nov 2026
SEC XBRL company facts (revenue, capex, R&D, backlog...)832 data points31 Dec 2014 to 10 Nov 2026
SEC Form 4 insider transactions124 records, 200 data points17 Aug 2016 to 19 Nov 2026
FINRA short interest (twice monthly)624 data points29 Dec 2017 to 30 Oct 2026
FINRA daily short sale volume (off-exchange)4172 data points1 Aug 2018 to 20 Nov 2026